Efficacy of Specific Peptides in Muscle Recovery

Two kinds of recovery

"Recovery" covers two different problems. One is bouncing back from hard training; the soreness and lost strength fade over a few days. The other is healing an injured tendon or ligament, which can take months because these tissues have a poor blood supply.

Peptides are sold for both. This page covers the four mentioned most often. BPC-157 and TB-500 are sold mainly for injuries; ipamorelin and CJC-1295 mainly for training recovery. For each one, rodent findings are kept apart from human data and user reports. The legal side is on our peptide legal status hub.

The table uses the site's evidence scale. "Moderate" means limited human data or strong animal data. "Emerging" means early human or consistent animal data, and "preliminary" means mostly early animal or cell work.

BPC-157: consistent in rats, untested in injured people

BPC-157 is a lab-made 15-amino-acid peptide based on a protein first isolated from gastric juice. In a 2008 rat study, animals with a crushed calf muscle got BPC-157 daily for 14 days, by injection into the abdominal cavity or as a skin cream. Both routes reduced bruising and swelling, and the treated rats regained full leg function.

A 2025 systematic review in the HSS Journal found 36 eligible studies, 35 of them preclinical. In those animal models BPC-157 improved healing in muscle and tendon as well as ligament and bone. A second 2025 review ties the effect to angiogenesis through VEGF receptor signaling and nitric oxide. Its authors think this may matter most in tissue with a poor blood supply, such as tendon.

As of October 2026, only three small human pilots have been published, none with a control group. The closest to recovery is a knee series: by the systematic review's count, 7 of 12 patients reported pain relief lasting over six months after joint injections. A 2025 IV pilot gave 2 adults 10 mg and then 20 mg infusions and found no side effects or lab changes. None of the pilots measured tendon or muscle healing, and the systematic review found no clinical safety data.

A University of Arkansas pilot (NCT07803250) plans to randomize about 30 rotator cuff surgery patients to daily subcutaneous BPC-157 or saline for 90 days, with MRI checks of tendon healing. As of October 2026 it isn't recruiting yet; the listed start is January 2027.

What users report. Forum users commonly report 250-500 mcg a day by subcutaneous injection, sometimes split into two doses, for 4-12 weeks. Some describe 1-2 mg a day for injuries. No dose-finding study backs any of these numbers. Many inject near the injury, though the crush study saw benefits from abdominal injections too and no human study has compared sites. Accounts range from clear improvement within weeks to nothing after a month or more. Some people describe fatigue or low mood in the first week.

The gap has several plausible causes. Rodent injuries are standardized and dosed precisely, while forum users are self-selected and often treat old injuries alongside rest and physical therapy. Gray-market product quality is also uneven (see peptide sourcing and quality control). As of October 2026, BPC-157 isn't approved as a drug anywhere, and WADA's 2026 Prohibited List bans it at all times under S0.

TB-500: a fragment sold on a protein's research

TB-500 is often called synthetic thymosin beta-4, which isn't accurate. In 2012, anti-doping chemists at Ghent University analyzed a TB-500 product and found Ac-LKKTETQ: residues 17-23 of the 43-amino-acid protein, with an acetyl group added.

Most healing research is on the full protein. A 2012 review describes thymosin beta-4 binding actin and helping stem and progenitor cells move into damaged tissue. In animal wounds it also reduced scarring. Far less work has tested the fragment, and FDA's compounding review says it has found no human exposure data for it. Human trials of the full protein tested eye drops and wound treatments rather than muscle or tendon. The ARISE-3 Phase 3 dry-eye trial missed its primary outcome measures, according to developer RegeneRx (2021).

What users report. Vendor guidance describes 2-2.5 mg twice weekly for 4-6 weeks, then monthly maintenance. Forum users describe a wider spread: 2-5 mg twice weekly, or 0.5-2 mg daily or every other day. Many can't tell whether their vials hold the fragment or the full protein. TB-500 is usually stacked with BPC-157 and sold as synergistic, but no study has compared the pair with either peptide alone. As of October 2026, WADA bans "thymosin-β4 and its derivatives e.g. TB-500" at all times under S2.3.

Ipamorelin and CJC-1295: more growth hormone, unproven recovery

These two act on the pituitary, not the injured tissue. Ipamorelin is a GHRP that works through the ghrelin receptor, and CJC-1295 is a GHRH analog. Both raise growth hormone, which in turn raises IGF-1. A 2020 review, drawing mostly on cell and animal work, describes IGF-1 activating satellite cells, the stem cells that repair muscle fibers. That's the case for faster recovery. No human trial has tested it: none has measured soreness or repair speed after training with either peptide.

The human data that exist call for caution:

• Ipamorelin's only efficacy trial was about gut recovery. In a 2014 Phase 2 trial, 117 adults recovering from bowel surgery got 0.03 mg/kg IV twice daily for up to 7 days. Median time to a first tolerated solid meal was 25.3 hours against 32.6 on placebo, which wasn't statistically significant.
• CJC-1295 raises hormones for days. In 2006 trials in healthy adults, one subcutaneous dose raised mean growth hormone 2- to 10-fold for 6 days or more. IGF-1 rose 1.5- to 3-fold for 9-11 days. Doses of 30-60 mcg/kg were best tolerated. Nobody measured muscle.
• More IGF-1 hasn't meant better function. In a 2-year trial of MK-677 (an oral, non-peptide secretagogue) at 25 mg a day, 65 older adults gained about 1.1 kg of fat-free mass while the placebo group lost about 0.5 kg. Strength and function didn't change. Fasting glucose rose and insulin sensitivity fell.

The "GH bleed" claim. Forum guides, including an earlier version of this page, say CJC-1295 with DAC (Drug Affinity Complex) causes a constant "bleed" of growth hormone that erases its natural pulses. The one human study that checked found otherwise. Pulse frequency and size were unchanged a week after a 60 or 90 mcg/kg dose in men aged 20-40. The baseline between pulses rose 7.5-fold, lifting mean growth hormone by 46% and IGF-1 by 45%. Whether that matters for recovery or safety hasn't been studied.

What users report. Most forum users describe the no-DAC form (Mod GRF 1-29) at 100-300 mcg with ipamorelin at bedtime, often 5 days on and 2 off. Vendor guidance for ipamorelin alone runs 200-300 mcg two to three times a day. No controlled trial has tested the combination. Flushing and water retention are the side effects users mention most.

FDA's compounding review cites a published study that found serious adverse events, including death, when ipamorelin was given by IV for gut motility. Our page on peptide health risks has more. As of October 2026, neither peptide is approved anywhere, and WADA bans both at all times under S2.2.4.

Myostatin blockers: approved for a disease, not for recovery

As of October 2026, one myostatin-targeted drug is approved. On September 11, 2026, FDA approved apitegromab (Isembyld), a prescription antibody injection, for spinal muscular atrophy (SMA) in patients 2 and older already on an SMN2-targeted treatment. Its main trial enrolled 188 people with SMA aged 2 to 21, so the approval says nothing about training recovery in healthy people.

No human study has tested the follistatin-344 or ACE-031 sold as research chemicals. ACE-031's own Phase 2 trial in boys with Duchenne muscular dystrophy was halted in 2011 after nose and gum bleeding and dilated skin blood vessels. WADA's 2026 list bans this class under S4.3 and names apitegromab there too.

What we still don't know

The main question is whether BPC-157 speeds tendon or muscle healing in people at all. The Arkansas trial, if it runs, would be the first randomized test. Nobody has shown that the TB-500 fragment does in people what the full protein does in animals. For ipamorelin and CJC-1295, no trial has measured a training-recovery outcome.

It's also unclear how much of the benefit users describe comes from placebo effects and the natural healing that happens over the same weeks. The community protocols collected on our bodybuilding dosing protocols page are untested in trials.